DEVELOPMENT AND MANUFACTURE OF MICROBIAL-DERIVED BIOPHARMACEUTICALS
Richter BioLogics is a leading and steadily growing biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with two cGMP-compliant manufacturing facilities in Germany.
We specialize in products derived from bacteria and yeasts. Over the past 35 years we gained substantial experience in the development and manufacture of product types that include recombinant proteins and peptides, antibody-like scaffolds (VHH/ Nanobodies, Fab fragments), plasmid DNA, and bacterial vaccines.
We move our clients projects forward: flexible, transparent, fast
Our Expertise
- Strong track record in microbial production of biopharmaceuticals
- Specialized in products derived from bacteria and yeasts
- Customer base includes established large pharmaceutical companies, small- and mid size pharma and biotech companies worldwide
- Production of commercial and both early- and late-stage products
- Project Management
- Strain-/ Process- and Analytical Development
- Bioassay development
Our Microbial Capabilities
- Headquarters in Hamburg and two GMP-compliant manufacturing facilities in Hannover and Bovenau, Germany
- GMP facilities approved by major regulatory bodies including EMA, FDA, PMDA, ANVISA, and MFDS
- Flexible production capabilities with fermenter volumes from 10L to 1500L and suitable DSP capacities
- Batch and fed-batch manufacture
- Methanol feeding for Pichia expression
- Continuous expansion of process development and quality control capacities at all sites
- Expansion of production capacities
Our company in numbers
How Richter BioLogics Overcomes the Challenges of the Covid-19 Pandemic
Latest News
Bovenau: Eine Eiche für Richter-Helm
Bovenau Der Bürgermeister der Gemeinde Bovenau, Daniel Ambrock, hat zusammen mit drei Gemeindevertretern dem Biotechnologie-Unternehmen Richter-Helm eine junge Stieleiche als Geschenk feierlich übergeben.
Implementation of a novel business process management system to increase efficiency in a CDMO company
As companies in pharma continue to grow, the way in which they operate and manage their sites
needs to adapt with increasing demands – how can a business process management system be
useful in facilitating these adaptations?
Biotechnologische Produktion ist unsere DNA
CORONA WAR EIN BOOSTER FÜR DIE BIOTECHNOLOGIE-BRANCHE.
Die Richter-Helm Biologics GmbH & Co. KG aus Hamburg ist seit über 30 Jahren ein Lohnhersteller für biopharmazeutische Produkte. Mit großer Expertise im Bereich der DNA-Impfstoffe war das Unternehmen während der Pandemie für große US Entwicklungsunternehmen ein wichtiger Produktionspartner.
Mit neuen Produktionsanlagen will das Unternehmen jetzt seine Kapazitäten für die kommenden Jahre weiter ausbauen.
A guide to the analysis of plasmid DNA
Plasmids are circular, double-stranded DNA molecules of various sizes originally found in bacteria, archaea and eukaryotic yeast. They replicate independently of chromosomal DNA and are easily genetically modified. Plasmids can be used for a variety of pharmaceutical purposes: as the active pharmaceutical ingredient (API) in DNA vaccines to prevent viral infections or cancer development; as critical raw material, starting material or ancillary material for viral vector production; or as template for mRNA-based products.
Delivering flexible and transparent manufacturing processes
Developing and manufacturing microbial-derived biopharmaceutical products require deep expertise and reliable solutions that can guide a project to success while meeting evolving industry standards. To this end, pharmaceutical companies need expert partners capable of bringing promising cures to the market on time, regardless of scale.
